Study GSI-136 in Healthy Young and Healthy Elderly Subjects
Completed · Phase 1 · Has a placebo group
Conditions studied: Alzheimer Disease, Healthy
In brief
This is a first-in-humans study of GSI-136, a drug being developed for the treatment of Alzheimer Disease. The main purpose of this study is to determine whether GSI-136 is safe and tolerable in healthy young and healthy elderly subjects. The amount of drug in the body and the effects of the drug on the body will also be evaluated at certain timepoints.
Key facts
- Study ID
- NCT00718731
- Run by
- Wyeth is now a wholly owned subsidiary of Pfizer
- People needed
- 80
- Starts
- 2008-03-01
- Expected to finish
- 2008-08-01
- Last updated by the study team
- 2010-04-02
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
Where it is running
- Study site — New York, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.